...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Placebo-Controlled Evaluation of Ritalin Side Effects
【24h】

Placebo-Controlled Evaluation of Ritalin Side Effects

机译:利他林副作用的安慰剂对照评估

获取原文
           

摘要

Objective. To address the frequency of side effects of Ritalin therapy in children with attention deficit hyperactivity disorder (ADHD) using the Barkley Side Effects Questionnaire (BSEQ) in a clinical setting.Design. Randomized double-blind placebo-controlled cross-over trial.Setting. A large rural tertiary care clinic.Patients. 234 consecutive children aged 5 through 15 years who met the Diagnostic and Statistical Manual of Mental Disorders (3rd ed, revised) criteria for ADHD were enrolled. Of these children, 206 had sufficient side effects data for analysis.Interventions. 0.3 mg/kg per dose and 0.5 mg/kg per dose Ritalin compared to placebo in separate 2-week trials. Each treatment was given three times a day for 7 consecutive days.Measurements and main results. Parents, blinded to the treatment assignment, assessed side effects via the BSEQ at baseline and at the end of each of the 4 treatment weeks. Univariate odds ratios (OR) were used to describe the magnitude of differences in observed side effects between Ritalin and placebo weeks of the trial for each of the items on the BSEQ. The frequency of the following side effects significantly increased with Ritalin therapy: insomnia (OR = 3.13, 95% confidence interval [CI] = (1.80,5.42)), appetite disturbance (OR = 19.00, 95% CI = (9.18,39.31)), stomachache (OR = 7.00, 95% CI = (3.29, 14.89)), headache (OR = 5.29, 95% CI = (2.51,11.15)), and dizziness (OR = 7.50, 95% CI = (1.93,29.13)). The frequency of the following side effects significantly decreased with Ritalin therapy: staring and daydreaming (OR = 0.47, 95% CI = (0.27,0.84)), irritability (OR = 0.33, 95% CI = (0.18,0.61)), anxiety (OR = 0.42, 95% CI = (0.23,0.76)), and nailbiting (OR = 0.19, 95% CI = (0.07, 0.53)). The incidence rates of the remaining BSEQ items did not differ significantly between the Ritalin and placebo weeks of the trial.Conclusion. The BSEQ proved to be clinically effective in tracking Ritalin side effects and should be incorporated into the routine evaluation and monitoring of ADHD patients for whom stimulants are prescribed.
机译:目的。在临床环境中使用Barkley副作用调查表(BSEQ)来解决注意缺陷多动障碍(ADHD)患儿利他林治疗的副作用发生频率。设计。随机双盲安慰剂对照的交叉试验。大型农村三级诊所。患者。入选了符合《精神障碍诊断和统计手册》(第三版,修订版)的234名5至15岁的儿童。在这些儿童中,有206名具有足够的副作用数据可供分析。在单独的2周试验中,与安慰剂相比,每剂0.3 mg / kg和每剂0.5 mg / kg利他林。每天连续3天每天3次给予每次治疗。测量和主要结果。父母对治疗分配不知情,在基线和每4个治疗周结束时通过BSEQ评估了副作用。对于BSEQ上的每个项目,单变量比值比(OR)用于描述利他林和安慰剂试验周之间观察到的副作用差异的大小。使用利他林治疗后,下列副作用的发生频率显着增加:失眠(OR = 3.13,95%置信区间[CI] =(1.80,5.42)),食欲不振(OR = 19.00,95%CI =(9.18,39.31) ),胃痛(OR = 7.00、95%CI =(3.29,14.89)),头痛(OR = 5.29、95%CI =(2.51,11.15))和头晕(OR = 7.50、95%CI =(1.93, 29.13))。利他林疗法可显着降低以下副作用的发生频率:凝视和做白日梦(OR = 0.47,95%CI =(0.27,0.84)),易怒(OR = 0.33,95%CI =(0.18,0.61)),焦虑(OR = 0.42,95%CI =(0.23,0.76))和指甲咬伤(OR = 0.19,95%CI =(0.07,0.53))。在试验的利他林和安慰剂周之间,其余BSEQ项目的发生率无显着差异。 BSEQ被证明在追踪Ritalin副作用方面具有临床效果,因此应纳入对开具兴奋剂的ADHD患者的常规评估和监测中。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号